Theriva Biologics, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Theriva Biologics (NYSE American: TOVX), a $3.9M market cap clinical-stage oncology company, executed a 1-for-30 reverse stock split effective December 1, 2026, reducing outstanding shares from 45,892,668 to approximately 1,529,756 shares and authorized shares from 350M to 11.67M. The split was implemented to maintain NYSE American listing compliance on minimum per-share price requirements. No shareholder approval was required under Nevada law; warrants, options, and equity plan shares are proportionally adjusted.
Why this rating
Reverse split is routine capital structure action to maintain exchange listing; does not alter business fundamentals, assets, or operations of this micro-cap stage company.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.